MedTrace Logo

A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis

NCT05491447 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2024-04-18

No results posted yet for this study

Summary

Phase 2 clinical trial conducted in 2 parts: Part 1 - Pharmacokinetics and Part 2 - Randomized and Placebo Controlled (subject and clinical assessors will be blinded). Study Product will be applied to AD BID days 1-28. There will be weekly visits from Baseline (day 1) through Day 29. There is a final follow up visit 2 weeks after.

Conditions

Interventions

DRUG

BMX-010

Ointment

DRUG

Placebo

Ointment

Sponsors & Collaborators

  • Innovaderm Research Inc.

    collaborator OTHER

  • BioMimetix JV, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-08
Primary Completion
2023-12-30
Completion
2024-04-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05491447 on ClinicalTrials.gov